The oral mucosal application on 1% chlorhexidine gel did not prevent the development of VAP in children between 3 months and 15 yrs admitted to our PICU. It also did not have any effect on the duration of ventilation, stay in ICU or hospital, and mortality. Further evaluation of chlorhexidine, particularly in higher concentrations, is required in the pediatric population.
Currently listed as Clinical Trials.gov NCT00597688.
Grant support was received from the Indian Council of Medical Research, New Delhi, India. The required 1% chlorhexidine and placebo gels were provided by ICPA Health Products Limited (233A, Adarsh Industrial Estate, Sahar Road, Chakala, Andheri East, Mumbai 400099, India). The funding agency did not have any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Pediatr Crit Care Med. 2012;13(5):E305-310. © 2012 Lippincott Williams & Wilkins